ABG-WTT Global Life Science Capital Partners GP Ltd
Long book
$12.3M
Q1 2026
Positions
2
Top-10 weight
100%
concentration
Last quarter
-3.9%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsABG-WTT Global Life Science Capital Partners GP Ltd is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $12.3M US long book across 2 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: CERIBELL INC, RAPID MICRO BIOSYSTEMS INC-A.
Over the last 9 quarters its long book ran on average 9pp per quarter behind the S&P 500, beating the index in 2 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-28.2%
Q2 2024
+20.0%
Q3 2024
-22.7%
Q4 2024
-17.2%
Q1 2025
+3.8%
Q2 2025
-30.2%
Q3 2025
+56.5%
Q4 2025
-18.3%
Q1 2026
-3.9%
Sector allocation
Healthcare 100%
Long book by quarter
What does ABG-WTT Global own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 18, 2026 | 2 | $12.3M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 2 | $15.0M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 2 | $18.7M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 2 | $26.8M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 4 | $38.3M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 4 | $43.7M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 3 | $20.1M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 3 | $30.0M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 3 | $41.5M | canonical | SEC ↗ |